Mandating any vaccine for all individuals is both problematic and unethical per Merck's guidelines
Contradictions to receiving the MMRII vaccine documented in Merck’s product insert include: 1) Persons who have experienced a severe allergic reaction or anaphylaxis to any MMR vaccine component, including gelatin and neomycin, should not be vaccinated with MMR. 2) Pregnant women should not receive this vaccine, and women seeking to become pregnant should avoid become pregnant for 3 months following MMR vaccination. 3) Individuals receiving immunosuppressive therapy. Vaccination with MMR should be delayed for 3 months following the administration of human immune globulin, blood, or plasma. 4) Persons with leukemia, lymphoma, blood dyscrasias and other malignant neoplasms affecting the lymphatic systems or bone marrow. 5) Individuals with febrile respiratory illness or other active febrile infection should avoid MMR vaccine. 6) MMR and other measles-containing vaccines are not recommended for HIV-infected persons with evidence of severe immunosuppression. 7) Persons with a family history of hereditary or congenital immunodeficiency should not be vaccinated with MMR until the immune competence of the recipient has been determined. 8) Individuals with untreated tuberculosis should not be vaccinated with MMR vaccine. Merck’s MMRII product insert also warns that caution should be taken when administering the vaccine to individuals with a history of cerebral injury, family or personal history of convulsions, or any other condition where stress related to fever should be avoided. Additionally, a person with thrombocytopenia may exacerbate their condition by receiving the MMR vaccine.
Both live measles and mumps vaccine are manufactured in chick embryo cell culture. Extreme caution should be taken when vaccinating individuals with a history of anaphylaxis or immediate hypersensitivity to eggs and Merck advises careful evaluation of the risks and benefits when considering vaccination in this population.
Rubella vaccine virus has been found in the breast milk of nursing mothers and there is documentation to support transmission of the virus to a nursing infant. Serological evidence of rubella infection and a case of mild clinical illness typical with an acquired rubella infection has also been documented in a nursing infant. As a result of these findings, Merck cautions the use of MMR vaccine in nursing women.
The content, ideas, and views in this article are those of the presenter(s); Arvesa does not claim ownership of the content or the information provided above. Arvesa’s intention in sharing information is to provide access to said information so that viewers may come to their own informed conclusion(s).
FAIR-USE COPYRIGHT DISCLAIMER:
Copyright Disclaimed under Section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, commenting, news reporting, teaching, scholarship and research. Fair use, including that of educational or personal use, is a use as permitted by copyright statute. Arvesa has uploaded this information as to preserve its integrity for educational purposes. Therefore, the use of material in this post constitutes a ‘FAIR USE’ of any such copyrighted material; the martial in this article is for research and educational purposes only.